1-4 of 4
Angel G. Galvez
Close
Sort by
Journal Articles

Is Initial Dasatinib-Blinatumomab Therapy for Ph-Positive ALL in Adults Cost Effective?

Jacob D. Bitran, Edward Nabrinsky, Shams Bufalino, Phillip Knouse, Angel G. Galvez
Journal: Blood
Blood (2021) 138 (Supplement 1): 4962.
https://doi.org/10.1182/blood-2021-144656
Published: 2021
Journal Articles

Clofarabine (CLO) Has Single Agent Activity in Relapsed and Refractory Non-Hodgkin Lymphoma (NHL) Including Rituximab (R)-Refractory Patients (pts).

Chadi Nabhan, MD, FACP, Jacob David Bitran, MD, FACP, Walter Fried, MD, Angel G. Galvez, MD, PhD, Laura Magid, Kathy Tolzien, Wendy Dewey, Parameswaran Venugopal, MD
Journal: Blood
Blood (2009) 114 (22): 921.
https://doi.org/10.1182/blood.V114.22.921.921
Published: 2009
Journal Articles

Surveillance Study of Temporary IVC Filters placed in Patients with VTE and Contraindications for Full Dose Anticoagulant Therapy

Angel G. Galvez, MD, PhD, Benjamin Parsons, D.O., Daniel Resnick, M.D., Morawa Ewelina, M.D., Abhilasha Radharkrishnan, M.D., Matthew Jimenez, M.D., Richard Messersmith, M.D.
Journal: Blood
Blood (2008) 112 (11): 3034.
https://doi.org/10.1182/blood.V112.11.3034.3034
Published: 2008
Journal Articles

Clofarabine (CLO) Is Active in Patients (pts) with Refractory and/or Relapsed Non-Hodgkin’s Lymphoma (NHL): A Phase I/II Study.

Chadi Nabhan, MD, FACP, Walter Fried, MD, Angel G. Galvez, MD, PhD, Parameswaran Venugopal, MD, Phillip Gozun, Jacob D. Bitran, MD, FACP
Journal: Blood
Blood (2007) 110 (11): 4462.
https://doi.org/10.1182/blood.V110.11.4462.4462
Published: 2007